“the cancer cachexia study should start later this year in a Phase III experience.”

In context

“ults and in pediatrics. As we've mentioned earlier, Serotype 3 is very important and is emerging as a very important serotype with up to 20% to 30% of the population actually developed serotype 3. So we're very pleased that we're now seeing what looks like best-in-class immunogenicity against serotype 3. On the pediatric front, as you mentioned, the study is ongoing. So we hope to provide additional data later this year. But everything we've seen so far suggests to us that we've got improved immunogenicity of PCV-25 versus our current vaccine. Just a reminder as well, we do have a fifth generation vaccine 30-plus, that's also now in preclinical development that we hope to launch in Phase I later this year. On ponsegromab, very quickly, we're excited about the data for cancer cachexia. And the cancer cachexia study should start later this year in a Phase III experience. And we stopped the development of the cardiovascular study. Albert Bourla: Thank you. And I want to also emphasize that the development strategy on PCV-30 plus involves the development of PCV-25, so refined strategy, which is development and regulatory, that will allow us to accelerate 30-plus by investing now in 25, which will come earlier, of course, to the market. And I think there was a question also on the penetration of PCV. But right now, both pediatric and adult, we have very, very high market share. We reported actually 87% market share. Next question, please. Operator: We'll go next to Courtney Breen with Bernstein. Please go ahead. Courtney Breen: Hi, everyone. Thanks for taking my call today. And thanks for the details on kind of how you're thinking about the R&D organization.”